Immunology
Xeris and Horizon enter partnership to develop teprotumumab
Xeris Biopharma and Horizon Therapeutics have signed a research partnership and option agreement for developing a ready-to-use, highly-concentrated, subcutaneous injection…
Horizon and Johns Hopkins partner for autoimmunity and inflammation research
Horizon Therapeutics and Johns Hopkins University School of Medicine have entered a multi-year scientific partnership for advancing autoimmunity and inflammation…
Jnana partners with Roche to discover drugs for multiple targets
Jnana Therapeutics and Roche have signed a second partnership and licence agreement to discover small-molecule drugs to treat cancer, immune-mediated and neurological ailments. The…
BioMed X and Sanofi partner to leverage AI for drug development
BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. Under the joint research project,…
Provention and Sanofi enter deal to launch teplizumab for type 1 diabetes
Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
European Commission’s approval of Mounjaro provides hope within obesity space
The type 2 diabetes (T2D) space recently witnessed a new approval: on 15 September, the European Commission (EC) authorised Eli…
Cell-based therapies set to become major players in the osteoarthritis market
Osteoarthritis (OA) is a slowly progressive joint disease that is a major cause of disability and pain among the elderly,…
Pfizer and CytoReason extend partnership for AI-driven drug discovery
Pfizer and CytoReason have expanded their multi-year collaboration to leverage the latter’s artificial intelligence (AI) technology to discover and develop the former’s drug…
Exploring opportunity and unmet needs in busy ulcerative colitis space
The ulcerative colitis (UC) therapeutics market has many options available and a relatively strong development pipeline. Despite this, there are…
US FDA grants approval for BMS’ Sotyktu to treat plaque psoriasis
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) to treat adult patients…
Rare Disease Spotlight- Oncology therapies dominate the orphan drug landscape
Rare diseases affect only a small percentage of the population, and since their pathophysiology has historically been poorly studied, there…
Sonoma signs deal to set up manufacturing centre for cell therapies
Sonoma Biotherapeutics has signed a lease agreement for setting up an 83,000ft² research and development (R&D) and manufacturing centre for…
Q32 Bio and Horizon partner to develop autoimmune disease treatment
Q32 Bio has signed a partnership and option agreement with Horizon Therapeutics for developing ADX-914 to treat autoimmune ailments. According to…
Amgen to acquire biopharma firm ChemoCentryx for $3.7bn
Amgen has signed a definitive agreement to acquire biopharmaceutical company ChemoCentryx for $52 for each share in cash or a total…
Gilead Sciences signs agreement to acquire MiroBio for $405m
Gilead Sciences has signed a definitive agreement for the acquisition of the complete outstanding share capital of MiroBio in a…